Why Shares of Cassava Sciences Rose 15% Today
Shares of Cassava Sciences (NASDAQ: SAVA) -- the biotech company responsible for Alzheimer's drug candidate simufilam -- are up 15% as of Thursday's market close after the company released interim data from a study funded by the National Institutes of Health.
Its treatment focuses on restoring the shape of a scaffolding protein in the brain. The theory is that the misfolding of that protein leads to inflammation and degeneration of neurons in the brain.
Image source: Getty Images.
Source Fool.com
